[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Intercommunal Aix-Pertuis\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100630619","variation-in-viscoelastic-properties-of-pulmonary-mucus-in-patients-undergoing-mechanical-ventilation-100630619",false,"NCT07490028","Variation in Viscoelastic Properties of Pulmonary Mucus in Patients Undergoing Mechanical Ventilation","Study of the Variation in Viscoelastic Properties of Pulmonary Mucus in Patients Undergoing Mechanical Ventilation With or Without NIV","RHEOREA","Inclusion Criteria:\n\n* Adult patients (\\> 18 years old)\n* Hospitalised in the intensive care unit of the CHIAP\n* Placed on mechanical ventilation, regardless of the length of hospitalisation before and after\n* French-speaking patients, able to understand the study information leaflet\n* No objection from the patient\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Patients deprived of their liberty, under guardianship or curatorship","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","Ventilator-associated pneumonia (VAP) is defined as an infection of the lung parenchyma in patients undergoing invasive mechanical ventilation for at least 48 hours. It is one of the types of pneumonia acquired in intensive care units (ICUs) and is one of the most common infections in this population, representing a major complication.\n\nThe diagnosis of VAP is based on three main criteria: clinical suspicion, adiological imaging, and microbiological cultures of the lower respiratory tract. However, these elements have significant limitations.\n\nNew rapid diagnostic techniques, such as multiplex polymerase chain reaction (PCR), can quickly identify pathogens and resistance mechanisms in just a few hours. These promising tools could reduce the time to initiate targeted treatment while limiting the excessive use of antibiotics. However, no single tool is currently accurate enough to diagnose VAP, and diagnosis is based on a combination of factors.\n\nToday, scores exist that can be used to assess the probability of PAVM, such as the CIPS. These are useful tools but lack specificity. The clinical, biological and radiological criteria used to calculate the score can also be observed in other pathologies. Thus, although they are sensitive to the detection of PAVM, they are often insufficient to establish a definitive diagnosis. They must be supplemented by other diagnostic approaches, such as microbiological cultures and more detailed imaging examinations, to obtain a more accurate assessment.\n\nIt is also essential to mention the importance of gaining a better understanding of the lung microbiome. Indeed, it appears to play a central role not only in the pathophysiology of MVAP, but also in its diagnosis and management.\n\nThe work of Fromentin et al. shows that it is possible to observe dysbiosis associated with a loss of microbial diversity and the onset of certain pulmonary infections. Thus, structural variations in mucus could reflect changes in the pulmonary microbiome.\n\nIt is therefore essential to remember that mucus plays an essential protective role in the respiratory tract by trapping particles, bacteria and pathogens, while facilitating their transport thanks to its viscoelastic properties. However, in mechanically ventilated patients, these mucociliary clearance mechanisms are often impaired, promoting the accumulation of secretions, bacterial proliferation and, ultimately, the onset of MVAP.\n\nThe work of Patarin and Giovanna and al. suggests that biochemical and microbiological changes in mucus could be a criterion for initiating treatment in recurrent pulmonary infections in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis. These observations suggest the potential value of early characterisation of mucus in ventilated patients in order to detect additional diagnostic clues that would enable rapid and appropriate treatment.",[25],"Ventilated Patient in Intensive Care",[27,28,29,30],"viscoelastic properties","mucus","mechanical ventilation","ventilator-associated pneumonia","RECRUITING","2026-03-19",{"date":34,"type":35},"2026-03-24","ACTUAL",{"date":37,"type":35},"2025-03-08",{"date":39,"type":21},"2026-03",{"name":41,"class":42},"Centre Hospitalier Intercommunal Aix-Pertuis","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100562737","immunity-markers-in-intensive-care-patients-and-ventilator-associated-pneumonia-100562737","NCT06607055","Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia","Monitoring of Immunity Markers in Intensive Care Patients and Link with Recurrence and Relapse of Ventilator-associated Pneumonia","IMMUNAIX","Inclusion Criteria:\n\n* Patient over 18 years old\n* Patient admitted in the Intensive Care Unit of the CHIAP\n* Patient under mechanical ventilation\n* Patient with infectious pneumonia\n* Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives\n* Patient beneficiary of French social security, whatever the regime\n\nExclusion Criteria:\n\n* Patient under 18 years old\n* Patient with severe neutropenia (neutrophils \\\u003C 0.5 G\u002FL)\n* Patient under immunosuppressive treatment\n* Use of corticosteroids (intravenous or oral) prior to ICU admission\n* Use of therapeutic antibodies\n* Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion\n* End of chemotherapy 6 months prior to inclusion\n* Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)\n* Patients with a decision to limit or discontinue active therapies, at the time of inclusion\n* Patients with an estimated ICU stay of less than 48 hours\n* Participation in an interventional study\n* Patient deprived of their liberty\n* Patient under tutorship or curatorship\n* Pregnant or breastfeeding woman",{"count":53,"type":21},40,"The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit.\n\nThe main questions it aims to answer are:\n\n* evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring\n* search an association between immunoplegia depth and severity of the initial state of shock\n* search an association between immunoplegia depth and viral reactivation\n* compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.",[56],"Pneumonia, Ventilator-Associated","2024-09-18",{"date":59,"type":35},"2024-09-23",{"date":61,"type":35},"2023-10-04",{"date":63,"type":21},"2025-09",{"name":41,"class":42},""]